The 340B rebate pilot has moved from applications to approved plans. The Health Resources and Services Administration now lists approvals for ten manufacturers, with January 1, 2027, start dates.1 Hospitals filed a new challenge on October 9, seeking declaratory and injunctive relief against the revised program.2
The August 3 notice opened a pathway for selected Medicare negotiation drugs from the 2026 and 2027 price-applicability years. Approved plans, rather than the earlier application calendar, now identify the products, platforms, and terms that affected organizations must examine.31
Manufacturers may choose whether to participate. Once the department approves an arrangement, covered entities acquiring an included product from that manufacturer must use the new method.4
What changes on January 1
The conventional model delivered the statutory price through an upfront discount. Replenishment systems let covered entities identify eligible dispenses, then buy matching replacement inventory at the reduced amount. The revised approach moves that value to a later payment. A covered entity buys at wholesale acquisition cost, reports the dispense, and waits for the difference between that amount and the ceiling price.5
The notice sets five operating rules:
- Scope. Eligible products are limited to the 11-digit National Drug Codes for selected drugs in the Medicare Drug Price Negotiation Program for applicability years 2026 and 2027. The rule applies during each product’s price applicability period, regardless of payer or indication.6
- Submission. Each approved design must give covered entities at least 45 calendar days after dispensing to report the required data. It must also allow for extenuating circumstances and later status changes.7
- Payment. A manufacturer must pay the covered entity or document a denial within 10 calendar days after receiving a complete submission. If information is incomplete, the payment clock restarts when the missing material arrives.8
- Denials. A manufacturer may not reject payment based on suspected diversion, Medicaid duplicate discounts, eligibility problems, or perceived insufficient full-price purchases. It must direct those concerns to the agency or use the statutory audit process.9
- Infrastructure. The manufacturer bears the technology-platform cost, must give affected covered entities 90 days’ notice, and must provide real-time reconciliation reports, quarterly price files, technical support, and data-security safeguards.10
The earlier litigation
The 2025 version never began. Hospital associations challenged it under the Administrative Procedure Act, and the United States District Court for the District of Maine entered a nationwide preliminary injunction on December 29, 2025. The First Circuit denied a stay after finding that the government had not shown that it considered hospitals’ reliance interests and major administrative costs. The department later withdrew that design, and the district court vacated and remanded the prior notices and approvals on February 10, 2026.11
The revised notice addresses cash flow, staffing, claims data, privacy, denial standards, dispute resolution, and small-entity effects. It also requires payment within 10 days after a complete submission, manufacturer-funded technology, and public posting of approved proposals.12
A separate D.C. Circuit decision defines the agency’s substantive authority. On July 21, 2026, the court held that Section 340B permits a rebate mechanism, but a manufacturer cannot impose one until the Secretary provides for and approves it. The court did not approve this pilot. It resolved a different dispute over unilateral action.13
A new challenge follows the approvals
On October 9, the American Hospital Association, the Maine Hospital Association, and four hospitals filed a new complaint in the District of Maine. They allege that the revised program understates administrative and financing costs and fails to account adequately for effects on patient care. Those are the plaintiffs’ allegations, not judicial findings.2
In my assessment, the earlier decisions make the distinction critical: authority to approve a rebate mechanism does not resolve whether the agency adequately justified this design. Organizations should track the new case alongside the posted manufacturer plans.
The SUSTAIN 340B Act would end the pilot
On August 5, a bipartisan group of six senators introduced the SUSTAIN 340B Act. The proposal would preserve point-of-purchase discounts as the standard method for providing the statutory price.14
The bill would also authorize covered entities to use contract pharmacies, subject to registration, standard agreement, recordkeeping, and audit provisions. It would direct the Secretary to end the pilot within one year after enactment, prohibit expansion during that period, and move the program toward a centralized data clearinghouse.15
The proposed legislation describes a different policy choice. HRSA’s posted plans still identify January 1, 2027, start dates.161 In my assessment, planning should account for the approved designs while tracking legislation and court action that could change implementation.
What covered entities should do now
The notice places claims-adjudication functions inside the drug-purchasing process. I see greater exposure at the handoffs among pharmacy operations, finance, technology, compliance, and outside vendors.17
With approved plans available, I would direct leadership teams to:
- Map included products by site, payer, and contract pharmacy.
- Model working-capital needs at the full acquisition price and test the 10-day payment assumption.8
- Confirm that systems can report each dispense within 45 days and quickly cure incomplete submissions.7
- Assign ownership for reconciliation, denials, disputes, and cash posting.
- Review each vendor’s security, access, retention, and permitted use of claims data.
- Test duplicate-discount and diversion controls without allowing manufacturers to decide issues reserved to the agency.9
- Revise agreements if data duties, payment flows, or financial risk shift among a covered entity, its administrator, and its contract pharmacies.
In my assessment, the practical task is to test the approved terms now: product mapping, data submission, money movement, and accountability across every affected site. Preserve the plan version used for each decision, and revisit assumptions when the agency or court acts.
Review court cases of interest, explore areas of experience, or see the author’s background.
Source notes
- Health Res. & Servs. Admin., 340B Rebate Model Pilot Program (last visited Oct. 21, 2026).
- Complaint ¶¶ 10–17, American Hospital Ass’n v. Kennedy, No. 1:26-cv-00515-LEW (D. Me. Oct. 9, 2026), ECF No. 1.
- Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. 48,883, 48,884, 48,902 (Aug. 3, 2026).
- Id. at 48,900 n.32.
- Novartis Pharmaceuticals Corp. v. Kennedy, No. 25-5177, slip op. at 3–7 (D.C. Cir. July 21, 2026); Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,885, 48,902–03.
- Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,902.
- Id.
- Id. at 48,903.
- Id.
- Id. at 48,902–03.
- American Hospital Association v. Kennedy, 164 F.4th 28, 31–34 (1st Cir. 2026); Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,885–86.
- Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,891–901, 48,902–03.
- Novartis Pharmaceuticals Corp., slip op. at 3, 13–14.
- Press Release, Office of Senator Jerry Moran, U.S. Senators Introduce Bipartisan Legislation to Support the 340B Drug Pricing Program (Aug. 5, 2026).
- SUSTAIN 340B Act, discussion draft §§ 2–3, 5 (Aug. 2026).
- Id. § 5; Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,884, 48,902.
- Notice Regarding 340B Rebate Model Pilot Program, 91 Fed. Reg. at 48,891–99, 48,902–03.